Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: hautnah 4/2019

06.09.2019 | Neurodermitis | Atopische Dermatitis

Therapie der atopischen Dermatitis

Zahlreiche Biologika in der Pipeline

verfasst von: Prof. Dr. Thomas Werfel

Erschienen in: hautnah | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten
share
TEILEN

Zusammenfassung

Anti-IL-22-Antikörper, Januskinase-Inhibitoren und H4-Rezeptor-Blocker könnten in Zukunft das Therapiearsenal gegen schwere Neurodermitisformen erweitern.
Literatur
1.
Zurück zum Zitat Gerbens LAA et al (2018) Methotrexate and azathioprine for severe atopic dermatitis: a 5‑year follow-up study of a randomized controlled trial. Br J Dermatol 178:1288–1296 CrossRef Gerbens LAA et al (2018) Methotrexate and azathioprine for severe atopic dermatitis: a 5‑year follow-up study of a randomized controlled trial. Br J Dermatol 178:1288–1296 CrossRef
2.
Zurück zum Zitat van der Schaft J et al (2015) Drug survival for ciclosporin A in a long-term daily practice cohort of adult patients with atopic dermatitis. Br J Dermatol 172:1621–1627 CrossRef van der Schaft J et al (2015) Drug survival for ciclosporin A in a long-term daily practice cohort of adult patients with atopic dermatitis. Br J Dermatol 172:1621–1627 CrossRef
4.
Zurück zum Zitat Werfel T (2018) Novel systemic drugs in treatment of atopic dermatitis: results from phase II and phase III studies published in 201 7/2018. Curr Opin Allergy Clin Immunol 18:432–437 CrossRef Werfel T (2018) Novel systemic drugs in treatment of atopic dermatitis: results from phase II and phase III studies published in 201 7/2018. Curr Opin Allergy Clin Immunol 18:432–437 CrossRef
5.
Zurück zum Zitat Werfel T et al (2018) New aspects in systemic treatment of atopic dermatitis. Hautarzt 69:217–224 CrossRef Werfel T et al (2018) New aspects in systemic treatment of atopic dermatitis. Hautarzt 69:217–224 CrossRef
6.
Zurück zum Zitat de Bruin-Weller M et al (2018) Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo- controlled, randomized phase III clinical trial (LIBERTY AD CAFE). Br J Dermatol 178:1083– 1101 CrossRef de Bruin-Weller M et al (2018) Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo- controlled, randomized phase III clinical trial (LIBERTY AD CAFE). Br J Dermatol 178:1083– 1101 CrossRef
7.
Zurück zum Zitat Blauvelt A et al (2019) Dupilumab does not affect correlates of vaccine-induced immunity: a randomized, placebo- controlled trial in adults with moderate- to-severe atopic dermatitis. J Am Acad Dermatol 80:158–167 CrossRef Blauvelt A et al (2019) Dupilumab does not affect correlates of vaccine-induced immunity: a randomized, placebo- controlled trial in adults with moderate- to-severe atopic dermatitis. J Am Acad Dermatol 80:158–167 CrossRef
8.
Zurück zum Zitat Rabe KF et al (2018) Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med 378:2475–2485 CrossRef Rabe KF et al (2018) Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med 378:2475–2485 CrossRef
9.
Zurück zum Zitat Castro M et al (2018) Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med 378:2486–2496 CrossRef Castro M et al (2018) Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med 378:2486–2496 CrossRef
10.
Zurück zum Zitat Wollenberg A et al (2018) Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment. J Allergy Clin Immunol Pract 6:1778–1780 CrossRef Wollenberg A et al (2018) Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment. J Allergy Clin Immunol Pract 6:1778–1780 CrossRef
11.
Zurück zum Zitat Treister AD et al (2018) Risk factors for dupilumab-associated conjunctivitis in patients with atopic dermatitis. JAMA Dermatol 154:1208–1211 CrossRef Treister AD et al (2018) Risk factors for dupilumab-associated conjunctivitis in patients with atopic dermatitis. JAMA Dermatol 154:1208–1211 CrossRef
12.
Zurück zum Zitat Ruzicka T et al (2017) Anti-Interleukin-31 receptor a antibody for atopic dermatitis. N Engl J Med 376:826–835 CrossRef Ruzicka T et al (2017) Anti-Interleukin-31 receptor a antibody for atopic dermatitis. N Engl J Med 376:826–835 CrossRef
13.
Zurück zum Zitat Kabashima K et al (2018) Nemolizumab in patients with moderate-to-severe atopic dermatitis: randomized, phase II, long-term extension study. J Allergy Clin Immunol 142(4):121–130 CrossRef Kabashima K et al (2018) Nemolizumab in patients with moderate-to-severe atopic dermatitis: randomized, phase II, long-term extension study. J Allergy Clin Immunol 142(4):121–130 CrossRef
14.
Zurück zum Zitat Wollenberg A et al (2019) Treatment of atopic dermatitis with tralokinumab, an anti-IL - 13 mAb. J Allergy Clin Immunol 143:135–141 CrossRef Wollenberg A et al (2019) Treatment of atopic dermatitis with tralokinumab, an anti-IL - 13 mAb. J Allergy Clin Immunol 143:135–141 CrossRef
15.
Zurück zum Zitat Simpson EL et al (2018) Efficacy and safety of lebrikizumab (an anti-IL - 13 monoclonal antibody) in adults with moderate-to- severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol 78:863–871 CrossRef Simpson EL et al (2018) Efficacy and safety of lebrikizumab (an anti-IL - 13 monoclonal antibody) in adults with moderate-to- severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol 78:863–871 CrossRef
16.
Zurück zum Zitat Guttman-Yassky E et al (2018) Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial. J Am Acad Dermatol 78:872–881 CrossRef Guttman-Yassky E et al (2018) Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial. J Am Acad Dermatol 78:872–881 CrossRef
17.
Zurück zum Zitat Brunner PM et al (2019) Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab. J Allergy Clin Immunol 143:142–154 CrossRef Brunner PM et al (2019) Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab. J Allergy Clin Immunol 143:142–154 CrossRef
18.
Zurück zum Zitat Guttman-Yassky E et al (2018) IL - 17C: a unique epithelial C ytokine with potential for  targeting across the spectrum of atopic dermatitis and psoriasis. J Invest Dermatol 138:1467–1469 CrossRef Guttman-Yassky E et al (2018) IL - 17C: a unique epithelial C ytokine with potential for  targeting across the spectrum of atopic dermatitis and psoriasis. J Invest Dermatol 138:1467–1469 CrossRef
19.
Zurück zum Zitat Schaper-Gerhardt K et al (2018) Histamine H 4 receptor and skin disorders. Br J Pharmacol Schaper-Gerhardt K et al (2018) Histamine H 4 receptor and skin disorders. Br J Pharmacol
21.
Zurück zum Zitat Guttman-Yassky E et al (2019) Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol 80(4):913–921.e9 CrossRef Guttman-Yassky E et al (2019) Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol 80(4):913–921.e9 CrossRef
Metadaten
Titel
Therapie der atopischen Dermatitis
Zahlreiche Biologika in der Pipeline
verfasst von
Prof. Dr. Thomas Werfel
Publikationsdatum
06.09.2019
Verlag
Springer Vienna
Schlagwort
Neurodermitis
Erschienen in
hautnah / Ausgabe 4/2019
Print ISSN: 1866-2250
Elektronische ISSN: 2192-6484
DOI
https://doi.org/10.1007/s12326-019-00346-w